TROPHAMET, a phase I/II trial of Avelumab and METhotrexate in low-risk gestational TROPHoblastic neoplasias as first line treatment

2024-515434-32-00 Protocol 69HCL18 0857 Phase I and Phase II (Integrated) - Other Ongoing, recruitment ended

Start 12 Feb 2020 · Status Ongoing, recruitment ended · 1 EU/EEA countries · 8 sites · Protocol 69HCL18 0857

Overview

Sponsor-declared trial summary

Phase Phase I and Phase II (Integrated) - Other
Status Ongoing, recruitment ended
Participants planned 26
Countries 1
Sites 8

Low-risk gestational trophoblastic neoplasia

Key facts

Sponsor
Hospices Civils De Lyon
Participant type
Patients
Age range
18-64 years
Gender
Female
Therapeutic area
Diseases [C] - Female Urogenital Diseases and Pregnancy Complications [C13]
Trial duration
12 Feb 2020 → ongoing
Decision date (initial)
2024-08-06
Transition trial
Yes
Low-intervention
No
Rare-disease indication
Yes
Vulnerable population
No

External identifiers

EU CT number
2024-515434-32-00
EudraCT number
2019-002814-38
ClinicalTrials.gov
NCT04396223

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Low-risk gestational trophoblastic neoplasia

VersionLevelCodeTermSystem organ class
20.0 LLT 10018211 Gestational trophoblastic tumor NOS 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Hospices Civils De Lyon

Sponsor organisation
Hospices Civils De Lyon
Address
3 Quai Des Celestins, Bp 2251 Bp 2251
City
Lyon Cedex 02
Postcode
69229
Country
France

Scientific contact point

Organisation
Hospices Civils De Lyon
Contact name
Pr Benoit YOU

Public contact point

Organisation
Hospices Civils De Lyon
Contact name
Annie IUNG

Locations

1 EU/EEA country · 8 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Ongoing, recruitment ended 26 8
Rest of world 0

Investigational sites

France

8 sites · Ongoing, recruitment ended
Assistance Publique Hopitaux De Paris
Oncologie médicale, 4 Rue De La Chine, 75020, Paris
Hospices Civils De Lyon
Oncologie médicale, 165 Chemin Du Grand Revoyet, 69310, Pierre Benite
Oncopole Claudius Regaud
Oncologie médicale, 1 Avenue Irene Joliot Curie, 31100, Toulouse
Centre de Coordination en Cancérologie François Baclesse
Oncologie médicale, 3 Avenue Général Harris, 14076, CAEN
Centre Antoine Lacassagne
Oncologie médicale, 33 Avenue De Valombrose, 06189, Nice Cedex 2
Centre De Lutte Contre Le Cancer Eugene Marquis
Oncologie médicale, Avenue La Bataille Flandre Dunkerque, Cs 44229, Rennes Cedex
Institut Bergonie
ONCOLOGIE MEDICALE, 180 R De Saint Genes, 229 Cours De L Argonne, Bordeaux
Institut Paoli Calmettes
Oncologie médicale, 232 Boulevard De Sainte Marguerite, Bp 156, Marseille

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
France 2020-02-12 2024-08-06 2024-08-06

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-07-05 France Acceptable
2024-08-06
2024-08-06
2 SUBSTANTIAL MODIFICATION SM-1 2024-12-10 France Acceptable
2025-01-31
2025-01-31
3 NON SUBSTANTIAL MODIFICATION NSM-1 2025-10-09 France Acceptable
2025-01-31
2025-10-09